vs
ANI PHARMACEUTICALS INC（ANIP）与Forestar Group Inc.（FOR）财务数据对比。点击上方公司名可切换其他公司
Forestar Group Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.1倍（$273.0M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 5.6%，领先5.5%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 9.0%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $-157.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs -9.6%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
ANIP vs FOR — 直观对比
营收规模更大
FOR
是对方的1.1倍
$247.1M
营收增速更快
ANIP
高出20.6%
9.0%
净利率更高
ANIP
高出5.5%
5.6%
自由现金流更多
ANIP
多$186.2M
$-157.1M
两年增速更快
ANIP
近两年复合增速
-9.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $273.0M |
| 净利润 | $27.5M | $15.4M |
| 毛利率 | — | 20.1% |
| 营业利润率 | 14.1% | 7.6% |
| 净利率 | 11.1% | 5.6% |
| 营收同比 | 29.6% | 9.0% |
| 净利润同比 | 367.5% | -6.7% |
| 每股收益（稀释后） | $1.14 | $0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPFOR
| Q4 25 | $247.1M | $273.0M | ||
| Q3 25 | $227.8M | $670.5M | ||
| Q2 25 | $211.4M | $390.5M | ||
| Q1 25 | $197.1M | $351.0M | ||
| Q4 24 | $190.6M | $250.4M | ||
| Q3 24 | $148.3M | $551.3M | ||
| Q2 24 | $138.0M | $318.4M | ||
| Q1 24 | $137.4M | $333.8M |
净利润ANIPFOR
| Q4 25 | $27.5M | $15.4M | ||
| Q3 25 | $26.6M | $86.9M | ||
| Q2 25 | $8.5M | $32.9M | ||
| Q1 25 | $15.7M | $31.6M | ||
| Q4 24 | $-10.3M | $16.5M | ||
| Q3 24 | $-24.2M | $81.5M | ||
| Q2 24 | $-2.3M | $38.7M | ||
| Q1 24 | $18.2M | $45.0M |
毛利率ANIPFOR
| Q4 25 | — | 20.1% | ||
| Q3 25 | — | 22.3% | ||
| Q2 25 | — | 20.4% | ||
| Q1 25 | — | 22.6% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 22.5% | ||
| Q1 24 | — | 24.9% |
营业利润率ANIPFOR
| Q4 25 | 14.1% | 7.6% | ||
| Q3 25 | 15.9% | 16.9% | ||
| Q2 25 | 6.6% | 11.2% | ||
| Q1 25 | 13.3% | 11.6% | ||
| Q4 24 | -2.3% | 8.7% | ||
| Q3 24 | -13.8% | 19.7% | ||
| Q2 24 | 3.7% | 16.2% | ||
| Q1 24 | 14.8% | 17.6% |
净利率ANIPFOR
| Q4 25 | 11.1% | 5.6% | ||
| Q3 25 | 11.7% | 13.0% | ||
| Q2 25 | 4.0% | 8.4% | ||
| Q1 25 | 8.0% | 9.0% | ||
| Q4 24 | -5.4% | 6.6% | ||
| Q3 24 | -16.3% | 14.8% | ||
| Q2 24 | -1.7% | 12.2% | ||
| Q1 24 | 13.2% | 13.5% |
每股收益（稀释后）ANIPFOR
| Q4 25 | $1.14 | $0.30 | ||
| Q3 25 | $1.13 | $1.70 | ||
| Q2 25 | $0.36 | $0.65 | ||
| Q1 25 | $0.69 | $0.62 | ||
| Q4 24 | $-0.45 | $0.32 | ||
| Q3 24 | $-1.27 | $1.59 | ||
| Q2 24 | $-0.14 | $0.76 | ||
| Q1 24 | $0.82 | $0.89 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $211.7M |
| 总债务越低越好 | — | $793.2M |
| 股东权益账面价值 | $540.7M | $1.8B |
| 总资产 | $1.4B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.44× |
8季度趋势，按日历期对齐
现金及短期投资ANIPFOR
| Q4 25 | $285.6M | $211.7M | ||
| Q3 25 | $262.6M | $379.2M | ||
| Q2 25 | $217.8M | $189.2M | ||
| Q1 25 | $149.8M | $174.3M | ||
| Q4 24 | $144.9M | $132.0M | ||
| Q3 24 | $145.0M | $481.2M | ||
| Q2 24 | $240.1M | $359.2M | ||
| Q1 24 | $228.6M | $416.2M |
总债务ANIPFOR
| Q4 25 | — | $793.2M | ||
| Q3 25 | — | $802.7M | ||
| Q2 25 | — | $872.8M | ||
| Q1 25 | — | $872.5M | ||
| Q4 24 | — | $806.8M | ||
| Q3 24 | — | $706.4M | ||
| Q2 24 | — | $706.1M | ||
| Q1 24 | — | $705.7M |
股东权益ANIPFOR
| Q4 25 | $540.7M | $1.8B | ||
| Q3 25 | $505.8M | $1.8B | ||
| Q2 25 | $436.8M | $1.7B | ||
| Q1 25 | $418.6M | $1.6B | ||
| Q4 24 | $403.7M | $1.6B | ||
| Q3 24 | $405.9M | $1.6B | ||
| Q2 24 | $455.8M | $1.5B | ||
| Q1 24 | $452.0M | $1.5B |
总资产ANIPFOR
| Q4 25 | $1.4B | $3.2B | ||
| Q3 25 | $1.4B | $3.1B | ||
| Q2 25 | $1.3B | $3.1B | ||
| Q1 25 | $1.3B | $3.0B | ||
| Q4 24 | $1.3B | $3.0B | ||
| Q3 24 | $1.3B | $2.8B | ||
| Q2 24 | $920.8M | $2.7B | ||
| Q1 24 | $914.5M | $2.6B |
负债/权益比ANIPFOR
| Q4 25 | — | 0.44× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.47× | ||
| Q1 24 | — | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $-157.0M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $-157.1M |
| 自由现金流率自由现金流/营收 | 11.8% | -57.5% |
| 资本支出强度资本支出/营收 | 0.5% | 0.0% |
| 现金转化率经营现金流/净利润 | 1.10× | -10.19× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $93.0M |
8季度趋势，按日历期对齐
经营现金流ANIPFOR
| Q4 25 | $30.4M | $-157.0M | ||
| Q3 25 | $44.1M | $256.3M | ||
| Q2 25 | $75.8M | $15.8M | ||
| Q1 25 | $35.0M | $-19.8M | ||
| Q4 24 | $15.9M | $-450.0M | ||
| Q3 24 | $12.5M | $119.2M | ||
| Q2 24 | $17.4M | $-61.7M | ||
| Q1 24 | $18.3M | $-59.2M |
自由现金流ANIPFOR
| Q4 25 | $29.1M | $-157.1M | ||
| Q3 25 | $38.0M | $255.6M | ||
| Q2 25 | $71.8M | $15.0M | ||
| Q1 25 | $32.5M | $-20.5M | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | $118.4M | ||
| Q2 24 | $13.0M | $-62.3M | ||
| Q1 24 | $13.7M | $-59.8M |
自由现金流率ANIPFOR
| Q4 25 | 11.8% | -57.5% | ||
| Q3 25 | 16.7% | 38.1% | ||
| Q2 25 | 34.0% | 3.8% | ||
| Q1 25 | 16.5% | -5.8% | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | 21.5% | ||
| Q2 24 | 9.4% | -19.6% | ||
| Q1 24 | 10.0% | -17.9% |
资本支出强度ANIPFOR
| Q4 25 | 0.5% | 0.0% | ||
| Q3 25 | 2.7% | 0.1% | ||
| Q2 25 | 1.9% | 0.2% | ||
| Q1 25 | 1.3% | 0.2% | ||
| Q4 24 | 1.3% | 0.0% | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | 3.2% | 0.2% | ||
| Q1 24 | 3.3% | 0.2% |
现金转化率ANIPFOR
| Q4 25 | 1.10× | -10.19× | ||
| Q3 25 | 1.66× | 2.95× | ||
| Q2 25 | 8.87× | 0.48× | ||
| Q1 25 | 2.23× | -0.63× | ||
| Q4 24 | — | -27.27× | ||
| Q3 24 | — | 1.46× | ||
| Q2 24 | — | -1.59× | ||
| Q1 24 | 1.00× | -1.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
